In a recent development, Scotland is set to approve the use of medications for prostate and lung cancers, among other conditions. The Scottish Medicines Consortium (SMC) has given the green light to five new medicines, including a groundbreaking treatment for certain prostate cancer patients and a drug for lung cancer patients. The new medications accepted for use on the NHS in Scotland cover various types of cancer and a life-threatening fungal infection.
Selinexor, also known as Nexpovio, has been approved for the treatment of adults with multiple myeloma, a form of cancer affecting the plasma cells in the bone marrow. This treatment can be used in combination with other drugs for patients who have undergone specific lines of treatment. Another approved drug, Pembrolizumab or Keytruda, is for adults with non-small cell lung cancer at high risk of recurrence post-surgery and chemotherapy. Additionally, Relugolix (Orgovyx) has been accepted for treating adult patients with advanced hormone-sensitive prostate cancer.
Prostate Cancer UK has welcomed the approval of Relugolix, lauding it as a “game-changer” for men in Scotland with advanced prostate cancer. This drug offers a more convenient and effective treatment option, allowing patients to take it at home as a tablet, eliminating the need for frequent clinic visits. Moreover, the drug is particularly beneficial for men unable to receive injections and is associated with a lower risk of heart problems compared to other treatments.
Apart from cancer treatments, the SMC has also sanctioned Rezafungin acetate, known as Rezzayo, for invasive candidiasis in adults and Faricimab (Vabysmo) for treating visual impairment caused by macular swelling due to a retinal vein blockage. Dr Scott Muir, Chairman of SMC, expressed satisfaction in accepting these new medicines, highlighting the personalized treatment options available through these approvals. Selinexor and Pembrolizumab offer additional treatment choices for multiple myeloma and post-surgery lung cancer patients, respectively.
This significant step in approving these medicines indicates progress in enhancing treatment options and access to innovative therapies for cancer and other life-threatening conditions in Scotland. The new approvals bring hope to patients and healthcare providers alike, offering advanced solutions to improve patient outcomes and quality of life.